At Wintermute Biomedical, our sole focus is to develop innovative solutions where current medicines are failing.
We are a global biopharmaceutical company with offices in the US and Australia. Founded in Missoula, Montana in 2012, we have discovered a next generation therapeutic, which we think will have a significant impact on the lives of many patients across the globe. We won’t rest until this new therapeutic is available to the many patients who desperately need it.
Wintermute Biomedical is driven by an experienced team of healthcare innovators, infectious disease experts and entrepreneurs.
Geoff is an engineer, entrepreneur and executive, with extensive experience in the healthcare sector. He has successfully co-founded, led, and exited a number of high-tech companies and is a recipient of the Prime Minister's Award for Science: New Innovator.
Tom is a Wintermute co-founder and inventor, with over 20 years experience in scientific research. He specializes in neuroscience and medical microbiology, with a particular focus on multidrug-resistant bacteria.
Priscilla is a healthcare innovator and experienced leader of research teams. She specializes in the research, development and translation of technologies to the health sector, both in corporate and start-up settings.
Paul is an engineer and investor with a track-record of pioneering and commercializing innovative technologies within the energy and healthcare sectors. With a unique ability to identify and nurture start-up companies, Paul joined Wintermute as the founding investor in 2012.
Matt has spent over 25 years in the development and commercialization of healthcare technology. He specialises in market development strategies, working with multinational healthcare companies and start-ups alike.
Wes is a Wintermute co-founder and a keen enthusiast for developing new and innovative solutions to address global health challenges, such as antimicrobial resistance.
Wintermute Biomedical is surrounded by world leading experts in microbiology, antimicrobial resistance, infectious disease and medicine.
Brett has over 20 years of pharmaceutical industry experience with significant exposure across the medicine discovery, development and commercialisation lifecycle. Through many leadership roles, Brett has led worldwide licensing, acquisition and venture capital backed transactions.
